Historical data shows that a consistent $500 monthly investment into Bicara Therapeutics Inc. Common Stock (BCAX) starting in 2020 would have turned a total investment of $21K into $26K today. This represents a total return of 28.3% over the 6-year period, compounding through dividend reinvestment and market growth.
The Impact of Dividend Reinvestment (DRIP)
Bicara Therapeutics Inc. Common Stock does not currently pay a notable dividend. For growth-focused stocks like BCAX, dollar cost averaging relies entirely on price appreciation. Over the 6-year period, the strategy successfully captured the stock's price movements, resulting in a final portfolio value of $26K without the need for dividend reinvestment.
BCAX vs. S&P 500 (SPY) Benchmark
When comparing this dollar cost averaging strategy against a broad market index,BCAX outperformed the S&P 500 ETF (SPY). The same $500 monthly contributions into SPY would have grown to $26K, compared to BCAX's $26K.